|
 |
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright ©ERS Journals Ltd 2008
Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia
1 VERDICT, 2 Divisions of General Internal Medicine, 4 Pulmonary and Critical Care Medicine, and 4 Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
CORRESPONDENCE: E. M. Mortensen, VERDICT, ALMD/UTHSCSA, Ambulatory Care (11C6), 7400 Merton Minter Boulevard, San Antonio, TX 78229, USA. Fax: 1 2105674423. E-mail: mortensene{at}uthscsa.edu
Keywords: Angiotensin-converting enzyme inhibitor, 3-hydroxl-3-methyl-glutaryl-CoA reductase inhibitor, mortality, pneumonia
Received: December 11, 2006
Accepted September 23, 2007
Recent studies suggest that statins and angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for some types of infections. The present study aimed to examine the association of outpatient use of these medications on 30-day mortality for subjects aged >65 yrs and hospitalised with community-acquired pneumonia.
A retrospective national cohort study was conducted using the Department of Veterans Affairs administrative data including subjects aged
In total, 8,652 subjects were identified with a mean age of 75 yrs, 98.6% were male, and 9.9% of subjects died within 30 days of presentation. In this cohort, 18.1% of subjects were using statins and 33.9% were using ACE inhibitors. After adjusting for potential confounders, current statin use (odds ratio (OR) 0.54, 95% confidence interval (CI) 0.42–0.70) and ACE inhibitor use (OR 0.80, 95% CI 0.68–0.89) were significantly associated with decreased 30-day mortality.
Use of statins and angiotensin-converting enzyme inhibitors prior to admission is associated with decreased mortality in subjects hospitalised with community-acquired pneumonia. Randomised controlled trials are needed to examine whether the use of these medications in patients hospitalised with community-acquired pneumonia may be beneficial.
65 yrs hospitalised with community-acquired pneumonia, and having 1 yr of prior Veterans Affairs outpatient care.
This article has been cited by other articles:
|
|
 |
|
  V. Chopra and S. A. Flanders Does Statin Use Improve Pneumonia Outcomes? Chest, November 1, 2009; 136(5): 1381 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R P Young, R Hopkins, and T E Eaton Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence Postgrad. Med. J., August 1, 2009; 85(1006): 414 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dublin, M. L Jackson, J. C Nelson, N. S Weiss, E. B Larson, and L. A Jackson Statin use and risk of community acquired pneumonia in older people: population based case-control study BMJ, June 16, 2009; 338(jun16_1): b2137 - b2137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Grossman Community-Acquired Pneumonia: Advances in Management ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 359 - 368. [Full Text] [PDF]
|
|
|
|
 |
|
 I. I. Siempos, K. Z. Vardakas, P. Kopterides, and M. E. Falagas Adjunctive therapies for community-acquired pneumonia: a systematic review J. Antimicrob. Chemother., October 1, 2008; 62(4): 661 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Effects of Statins and ACE Inhibitors in CAP and Influenza Journal Watch Infectious Diseases, April 2, 2008; 2008(402): 2 - 2. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |